Detalles de la búsqueda
1.
Semi-Quantitative MALDI Measurements of Blood-Based Samples for Molecular Diagnostics.
Molecules
; 27(3)2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35164262
2.
Explaining multivariate molecular diagnostic tests via Shapley values.
BMC Med Inform Decis Mak
; 21(1): 211, 2021 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34238309
3.
Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach.
Int J Mol Sci
; 21(3)2020 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32012941
4.
Improving the power of gene set enrichment analyses.
BMC Bioinformatics
; 20(1): 257, 2019 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101008
5.
A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data.
BMC Bioinformatics
; 20(1): 325, 2019 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31196002
6.
Robust identification of molecular phenotypes using semi-supervised learning.
BMC Bioinformatics
; 20(1): 273, 2019 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31138112
7.
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist
; 24(6): e251-e259, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30139835
8.
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
BMC Cancer
; 18(1): 310, 2018 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29558888
9.
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Lancet Oncol
; 15(7): 713-21, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24831979
10.
Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance.
J Mass Spectrom Adv Clin Lab
; 30: 51-60, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38074293
11.
Predicting prognosis in COVID-19 patients using machine learning and readily available clinical data.
Int J Med Inform
; 155: 104594, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34601240
12.
Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test.
Cancers (Basel)
; 13(13)2021 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34206321
13.
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
J Pancreat Cancer
; 7(1): 8-19, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33786412
14.
A proposal for score assignment to characterize biological processes from mass spectral analysis of serum.
Clin Mass Spectrom
; 18: 13-26, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34820522
15.
Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer.
Cancers (Basel)
; 12(9)2020 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32899818
16.
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors.
Clin Cancer Res
; 26(19): 5188-5197, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32631957
17.
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
J Immunother Cancer
; 7(1): 91, 2019 03 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30925943
18.
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Lung Cancer
; 117: 64-69, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29395121
19.
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.
Cancer Immunol Res
; 6(1): 79-86, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29208646
20.
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
J Thorac Oncol
; 8(4): 443-51, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23370367